OPKO Health, Inc. (TLV:OPK)
Market Cap | 4.22B |
Revenue (ttm) | 2.60B |
Net Income (ttm) | -193.86M |
Shares Out | n/a |
EPS (ttm) | -0.28 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 123,530 |
Average Volume | 373,033 |
Open | 656.90 |
Previous Close | 651.80 |
Day's Range | 638.60 - 658.20 |
52-Week Range | 425.20 - 734.40 |
Beta | 1.71 |
RSI | 50.65 |
Earnings Date | May 8, 2025 |
About OPKO Health
OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company’s Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women’s health, and correctional healthcare to physician offices, clinics, hospitals, employers,... [Read more]
Financial Performance
In 2024, OPKO Health's revenue was $713.14 million, a decrease of -17.41% compared to the previous year's $863.50 million. Losses were -$53.22 million, -71.82% less than in 2023.
Financial numbers in USD Financial StatementsNews

OPKO and Entera partner to develop obesity pill
OPKO Health and Entera Bio are partnering to develop a once-daily pill for patients with obesity and other disorders, the companies said on Monday.

Labcorp to buy certain assets of OPKO unit BioReference Health
Labcorp (NYSE:LH) stock gains after deal to acquire OPKO Health (OPK) unit BioReference Health's cancer-focused units for up to $225M. Read more here.

Labcorp Announces Acquisition of Select Assets of BioReference Health's Innovative Oncology and Related Clinical Testing Services Businesses
Transaction to extend Labcorp's leadership in oncology and expand access to the company's high-quality clinical laboratory services BURLINGTON, N.C. and MIAMI , March 11, 2025 /PRNewswire/ -- Labcorp ...
Decoding OPKO Health Inc (OPK): A Strategic SWOT Insight
Decoding OPKO Health Inc (OPK): A Strategic SWOT Insight

Opko Health (OPK) Q4 2024 Earnings Call Transcript
OPK earnings call for the period ending December 31, 2024.
OPKO Health, Inc. (OPK) Q4 2024 Earnings Call Transcript
OPKO Health, Inc. (NASDAQ:OPK) Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ETCompany ParticipantsYvonne Briggs - Alliance Advisors IRDr.

OPKO Health Reports Fourth Quarter 2024 Business Highlights and Financial Results
MIAMI, Feb. 27, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and 12 months ended December 31, 2024. Highlights from the four...

OPKO Health to Present at the 43rd Annual J.P. Morgan Healthcare Conference
MIAMI, Jan. 09, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) announced today that management will be participating in the 43r d Annual J.P. Morgan Healthcare Conference, being held January...

NextPlat to Showcase OPKO Healthcare Products at the 2024 China International Natural Health & Nutrition Expo
OPKO Healthcare's Veterinary Care Products to be Introduced at Asia's Largest Health and Nutrition Tradeshow Company Invited to Present at Special Event Hosted by U.S. Consulate General During the Exp...

NextPlat Reports $49.8 Million in Consolidated Revenue for the Nine Months Ended September 30, 2024, Representing a 136% Increase Over 2023 Results
Company Sees Initial Sales Momentum in China for OPKO Health Products as it Prepares for the Launch of its Florida Sunshine Brand of Vitamins and Supplements COCONUT GROVE, Fla. , Nov. 14, 2024 /PRNew...

Opko Health (OPK) Q3 2024 Earnings Call Transcript
OPK earnings call for the period ending September 30, 2024.
OPKO Health, Inc. (OPK) Q3 2024 Earnings Conference Call Transcript

ModeX Therapeutics Secures $35 Million BARDA Supplement to Develop COVID Multispecific Antibodies and $16 Million to Initiate Influenza Program
WESTON, Mass., Oct. 07, 2024 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO Health, Inc. (NASDAQ: OPK) company, announces it has been awarded $35 million of additional funding under an existing ...

NextPlat Secures Four-Year Extension of OPKO Healthcare E-Commerce Program in China and Agrees to the Expansion of the Program into Japan
Company to Support the Sales and Marketing of OPKO's Products on Additional E-Commerce Platforms and on Social Media Channels in China and into the Large Japanese Health and Wellness Market COCONUT GR...
OPKO Health's ModeX Therapeutics Appoints Dr. Giovanni Abbadessa as Chief Medical Officer as Pipeline Advances into Clinical Development
WESTON, Mass., Sept. 23, 2024 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO Health, Inc. (NASDAQ: OPK) company, today announced the appointment of Giovanni Abbadessa, M.D., Ph.D. as Chief Medi...

Labcorp Completes Acquisition of Select Assets of BioReference Health's Diagnostics Business from OPKO Health
Enhances Labcorp's laboratory services network and expands access to its clinical services BURLINGTON, N.C. and MIAMI , Sept.

OPKO Health Reports Second Quarter 2024 Business Highlights and Financial Results
MIAMI, Aug. 07, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and six months ended June 30, 2024. Highlights from the second ...

OPKO Health and HealthCare Royalty Enter into $250 Million Note Purchase Agreement Secured by NGENLA's Profit Share Payments
MIAMI, July 17, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) announces it has entered into a $250 million non-dilutive note purchase agreement with HealthCare Royalty (HCRx) secured by OPK...

OPKO Health to Participate in the Jefferies Global Healthcare Conference
MIAMI, May 31, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) announced today that management will be participating in the Jefferies Global Healthcare Conference, being held June 4-6, 2024 a...

OPKO Health, Inc. (OPK) Q1 2024 Earnings Call Transcript
Start Time: 16:30 January 1, 0000 5:21 PM ET OPKO Health, Inc. (NASDAQ:OPK) Q1 2024 Earnings Conference Call May 07, 2024, 16:30 PM ET Company Participants Phil Frost - Chairman and CEO Elias Zerhoun...

OPKO Health Reports First Quarter 2024 Business Highlights and Financial Results
MIAMI, May 07, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three months ended March 31, 2024. First quarter business highlights i...

OPKO Health to Report First Quarter 2024 Financial Results on May 7, 2024
MIAMI, May 03, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three months ended March 31, 2024 after the close of the U.S. financial ...

Labcorp Announces Acquisition of Select Assets of BioReference Health's Diagnostics Business
Transaction to enhance Labcorp's laboratory services network and expand access to the company's high-quality clinical laboratory services BURLINGTON, N.C. and MIAMI , March 28, 2024 /PRNewswire/ -- L...

AIDS Clinical Trial Group Presents Results from Phase 1 Study of ModeX Trispecific Antibody for the Treatment and Prevention of HIV
• Study delivers first clinical safety and pharmacokinetic data as proof of concept for the use of multispecific antibodies in humans • Candidate showed similar half-life to standard monoclonal antibo...